Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

A temporally resolved CRISPR-Cas9 screen reveals DAC-induced DNA damage drives trans-cell cycle cytotoxicity that depends on ...

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

CRISPR technology has radically transformed genetic research, and at the forefront of this transformation is CRISPR screening ...

Northwestern Medicine investigators have developed a new avenue to reprogram compromised immune cells to act against tumors, ...

The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

Beans are a key food at the dietary level, boasting high nutritional value and constituting the most directly consumed legume ...

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

Bristol Myers Squibb's FDA nod for Breyanzi (liso-cel) in relapsed/refractory CLL/SLL boosts its CAR T-cell portfolio, ...

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell ...

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...